↓ Skip to main content

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

Overview of attention for article published in BMC Cancer, March 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)

Mentioned by

twitter
1 tweeter
patent
1 patent

Citations

dimensions_citation
66 Dimensions

Readers on

mendeley
54 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
Published in
BMC Cancer, March 2016
DOI 10.1186/s12885-016-2162-z
Pubmed ID
Authors

Melanie Mediavilla-Varela, Kingsley Boateng, David Noyes, Scott J. Antonia

Abstract

Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as cancer-associated fibroblasts (CAFs) and CAFs contribute actively to the malignant phenotype, we believe that anti-fibrotic drugs have the potential to be repurposed as anti-cancer drugs. The effects of pirfenidone alone and in combination with cisplatin on human patient-derived CAF cell lines and non-small cell lung cancer (NSCLC) cell lines were examined. The impact on cell death in vitro as well as tumor growth in a mouse model was determined. Annexin V/PI staining and Western blot analysis were used to characterize cell death. Synergy was assessed with the combination index method using Calcusyn software. Pirfenidone alone induced apoptotic cell death in lung CAFs at a high concentration (1.5 mg/mL). However, co-culture in vitro experiments and co-implantation in vivo experiments showed that the combination of low doses of cisplatin (10 μM) and low doses of pirfenidone (0.5 mg/mL), in both CAFs and tumors, lead to increased cell death and decreased tumor progression, respectively. Furthermore, the combination of cisplatin and pirfenidone in NSCLC cells (A549 and H157 cells) leads to increased apoptosis and synergistic cell death. Our studies reveal for the first time that the combination of cisplatin and pirfenidone is active in preclinical models of NSCLC and therefore may be a new therapeutic approach in this disease.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 54 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 15%
Researcher 8 15%
Student > Master 8 15%
Student > Bachelor 7 13%
Professor 4 7%
Other 9 17%
Unknown 10 19%
Readers by discipline Count As %
Medicine and Dentistry 15 28%
Biochemistry, Genetics and Molecular Biology 10 19%
Pharmacology, Toxicology and Pharmaceutical Science 7 13%
Agricultural and Biological Sciences 4 7%
Computer Science 1 2%
Other 4 7%
Unknown 13 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2022.
All research outputs
#6,512,265
of 21,528,315 outputs
Outputs from BMC Cancer
#1,702
of 7,773 outputs
Outputs of similar age
#89,592
of 279,687 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 21,528,315 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 7,773 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,687 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them